The following table lists the largest mergers and acquisitions in the pharmaceutical and biotechnology industry (those over $10 billion). Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values).
This list is incomplete, you can help by expanding it
R | Year | Purchaser | Target | Transaction type [1] | Value — with debt (in billions USD) | Value — with debt (adjusted for inflation) | Ref |
---|---|---|---|---|---|---|---|
1 | 1999 | Pfizer | Warner-Lambert | Acquisition | 111.8 | 204 | [2] |
2 | 2000 | Glaxo Wellcome plc | SmithKline Beecham | Merger (formed GlaxoSmithKline) | 76.0 | 134 | |
3 | 2019 | Bristol-Myers Squibb | Celgene | Acquisition | 74.0 — 95.0 | 88 — 113 | [3] |
3 | 2004 | Sanofi | Aventis | Acquisition | 73.5 | 104 | |
4 | 2015 | Actavis | Allergan, Inc | Acquisition | 70.5 | 91 | [4] [5] [6] |
5 | 2009 | Pfizer | Wyeth | Acquisition | 68.0 | 97 | |
6 | 2002 | Pfizer | Pharmacia | Acquisition | 64.3 | 109 | [7] |
7 | 2018 | Takeda Pharmaceutical | Shire | Acquisition | 62.0 | 75 | [8] |
8 | 2016 | Bayer | Monsanto | Acquisition | 54.5 — 63.5 | 69 — 81 | |
9 | 2009 | Merck & Co. | Schering-Plough | Acquisition | 47.1 | 67 | [9] |
10 | 2009 | Roche | Genentech | Acquisition | 44.0 | 62 | |
11 | 2014 | Medtronic | Covidien | Acquisition | 42.3 | 54 | |
12 | 2015 | Teva Pharmaceutical Industries | Actavis | Business Unit | 40.5 | 52 | |
13 | 2010 | Novartis | Alcon | Acquisition | 39.3 | 55 | |
14 | 2016 | Shire | Baxalta | Acquisition Unit | 32.0 — 35.0 | 41 — 44 | |
15 | 2016 | Abbott Laboratories | St Jude Medical | Acquisition | 30.5 | 39 | |
16 | 1998 | Astra AB | Zeneca | Merger (formed AstraZeneca) | 30.4 | 57 | |
17 | 2017 | Johnson & Johnson | Actelion | Acquisition | 30.0 | 37 | |
18 | 1996 | Ciba-Geigy | Sandoz | Merger (formed Novartis) | 29.0 | 56 | |
19 | 2006 | Boston Scientific Abbott Laboratories | Guidant | Acquisition | 27.2 | 41 | |
20 | 1999 | Pharmacia & Upjohn | Monsanto | Merger | 25.2 | 46 | |
21 | 2016 | Abbott Laboratories | St Jude Medical | Acquisition | 25.0 — 30.5 | 32 — 39 | |
22 | 2015 | AbbVie | Pharmacyclics | Acquisition | 21.0 | 27 | |
23 | 2014 | Actavis | Forest Laboratories | Acquisition | 20.7 | 27 | |
24 | 2011 | Sanofi | Genzyme Corporation | Acquisition | 20.1 | 27 | |
25 | 2012 | Johnson & Johnson | Synthes | Acquisition | 19.7 | 26 | |
26 | 2006 | Bayer | Schering | Acquisition | 18.4 | 28 | |
27 | 2016 | Quintiles | IMS Health | Merger (formed QuintilesIMS) | 17.6 | 22 | |
28 | 2015 | Pfizer | Hospira | Acquisition | 17.0 | 22 | |
29 | 2014 | Merck Group | Sigma-Aldrich | Acquisition | 17.0 | 22 | |
30 | 2001 | Amgen | Immunex | Acquisition | 16.8 | 29 | |
31 | 2006 | Johnson & Johnson | Pfizer Consumer Health | Business Unit | 16.6 | 25 | |
32 | 2014 | Novartis | GlaxoSmithKline Oncology | Business Unit | 16.0 | 21 | |
33 | 2015 | Valeant | Salix Pharmaceuticals | Acquisition | 15.8 | 20 | |
34 | 2007 | AstraZeneca | MedImmune | Acquisition | 14.7 | 22 | |
35 | 2007 | Schering Plough | Organon International | Acquisition | 14.5 | 21 | |
36 | 1995 | Glaxo | Wellcome | Acquisition | 14.2 | 28 | |
37 | 2014 | Bayer | Merck & Co Consumer Health | Business Unit | 14.2 | 18 | |
38 | 2014 | Zimmer Inc. | Biomet Inc. | Acquisition | 13.4 | 17 | |
39 | 2019 | Amgen | Otezla (drug programme) | Acquisition | 13.4 | 16 | |
40 | 2006 | Merck Group | Serono | Acquisition | 13.2 | 20 | |
41 | 2018 | GlaxoSmithKline | GlaxoSmithKline–Novartis Consumer Healthcare | Acquisition | 13.0 | 16 | |
42 | 2016 | Boehringer Ingelheim | Sanofi Animal Health (Merial) | Business Unit | 12.4 | 16 | |
43 | 2017 | Gilead Sciences | Kite Pharma | Acquisition | 11.9 | 15 | |
44 | 2018 | Sanofi | Bioverativ | Acquisition | 11.6 | 14 | |
45 | 2011 | Gilead Sciences | Pharmasset | Acquisition | 11.2 | 15 | |
46 | 2013 | Amgen | Onyx Pharmaceuticals | Acquisition | 10.4 | 14 | |
47 | 2020 | AbbVie | Allergan | Acquisition | 63.0 | 74 | |
48 | 2024 | Novo Holdings A/S | Catalent | Acquisition | 16.5 | 17 | [10] [11] |
Rank | Year | Purchaser | Target | Value (in billions USD) | Value (adjusted for inflation) | |
---|---|---|---|---|---|---|
1 | 2015 | Pfizer | Allergan, plc | 160 | 206 | In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation). However, this deal was cancelled in April 2016 due to new US tax inversion rules. [12] [13] Had this transaction been completed, this would have been the largest within this industry. |
2 | 2014 | Pfizer | Astra Zeneca | 123 | 158 | Significant concerns were raised by the UK Government over job security, in the end leading to a deal being abandoned due to resistance from the AstraZeneca Board. [14] |
3 | 2014 | Pfizer | Astra Zeneca | 106 | 137 | AstraZeneca claimed the deal undervalued the company. [15] |
4 | 2014 | Pfizer | Astra Zeneca | 99 | 127 | AstraZeneca claimed the deal undervalued the company. [16] |
5 | 1999 | Pfizer | Warner–Lambert | 82.4 | 151 | Pfizer made a hostile bid, just after the announcement of a $72 billion deal with Wyeth, the eventual purchase price would be in excess of $90 billion. [17] [18] [19] |
6 | 1999 | Wyeth | Warner–Lambert | 72 | 132 | Wyeth confirmed it has agreed a $200 billion deal with Warner–Lambert, causing Pfizer to make a hostile bid, just after the announcement. [17] [18] [19] |
7 | 1999 | Wyeth | Warner–Lambert | 65 | 119 | The two companies discussed a potential merger, uniting two of the largest pharmaceutical companies. This was eventually thwarted by Pfizer, in order to maintain control of the blockbuster drug - Lipitor. [20] [21] |
8 | 2016 | Bayer AG | Monsanto Company Inc. | 65 | 83 | Bayer advanced talks with Monsanto's management and subsequently raised its off by $3 billion, to more than $65 billion - which represented a 2 percent increase on its previous offer. The eventual purchase price would be more than $66 billion. [22] [23] |
9 | 2018 | Takeda Pharmaceutical | Shire | 62.5 | 76 | Third bid, unanimously rejected by the Shire Board, who concluded that it significantly undervalue the company, its growth prospects as well as pipeline. [24] |
10 | 2016 | Bayer AG | Monsanto Company Inc. | 62 | 79 | Bayer initially opened negotiations with an offer of $125 per Monsanto share, however management felt this undervalued the company. [22] |
11 | 2018 | Takeda Pharmaceutical | Shire | 61 | 74 | Second bid, unanimously rejected by the Shire Board, who concluded that it significantly undervalue the company, its growth prospects as well as pipeline. [24] |
12 | 2018 | Takeda Pharmaceutical | Shire | 58.2 | 71 | First bid, unanimously rejected by the Shire Board, who concluded that it significantly undervalue the company, its growth prospects as well as pipeline. [24] |
13 | 2014 | Valeant Pharmaceuticals | Allergan, Inc | 54 | 70 | Valeant had pursued Botox-maker Allergan for six months. After a protracted court battle with Valeant, Bill Ackman and his Pershing Square Capital Management hedgefund on one side (which then owned 10% of Allergan) and Allergan on the other, Actavis entered the fray with a $66 billion white knight bid. [25] |
14 | 2014 | AbbVie | Shire Pharmaceuticals | 54 | 70 | The two companies had agreed to a $54 billion deal that would allow AbbVie to move its headquarters overseas to Europe, reducing their corporate tax rate. However, the U.S. Treasury passed laws, tightening down on tax inversion deals just before the merger was completed, making the agreement much less profitable for AbbVie.[ citation needed ] |
15 | 2014 | Valeant Pharmaceuticals | Allergan, Inc | 53.3 | 69 | Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] |
16 | 2014 | Valeant Pharmaceuticals | Allergan, Inc | 49.4 | 64 | Valeant raised its unsolicited offer for Allergan Inc. to $49.4 billion, adding more cash to the bid in an effort to win backing from Allergan and its investors, with the value of each share rising to $166.16 per Allergan share. [27] |
17 | 2015 | Monsanto Company Inc. | Syngenta AG | 47 | 60 | Monsanto dropped its hostile bid for Syngenta, refocusing on its five-year plan to double earnings and avoid a backlash from large shareholders. [28] Subsequently, Bayer offered to purchase Monsanto, with ChemChina offering to acquire Syngenta. |
18 | 2014 | Monsanto Company Inc. | Syngenta AG | 45 | 58 | Syngenta rejecteded another unsolicited offer from Monsanto, worth $45 billion, with management saying it undervalued the company and a merger would carry significant risks. Monsanto offered to acquire the company at a price of 449 Swiss francs per Syngenta share, with approximately 45% of the price paid in cash. [29] [30] |
19 | 2014 | Valeant Pharmaceuticals | Allergan, Inc | 45 | 58 | Valeant Pharmaceuticals and activist investor Bill Ackman offered to buy Botox maker Allergan, proposing a cash-and-stock deal worth about $152.89. [31] |
20 | 2014 | Monsanto Company Inc. | Syngenta AG | 40 | 51 | Monsanto weighed $40 billion unsolicited bid for Swiss rival, Syngenta aiming to avoid US corporation taxes. Monsanto and Syngenta held preliminary talks with both sets of advisers in the preceding few months, with talks centered on a combination. However, Syngenta's management decided against negotiations. [32] |
21 | 2015 | Teva Pharmaceutical Industries | Mylan | 40 | 51 | In April, Teva offered to acquire Mylan for $40 billion, [33] only a fortnight after Mylan offered to acquire Perrigo for $29 billion. [34] Teva's offer for Mylan is contingent on Mylan abandoning its acquisition of Perrigo. [35] Mylan stated in June 2015 that Teva's disclosure that it had a 1.35 percent stake in Mylan violated US anti-trust rules. |
22 | 2015 | Mylan | Perrigo | 26 | 33 | In order for the hostile takeover to go through successfully, Mylan needed 50% of Perrigos shares to be tendered under the deal. However, only 40% or 58 million shares were tendered and the hostile takeover fell through. [36] |
23 | 2004 | Johnson & Johnson | Guidant | 25.4 | 41 | Johnson & Johnson announced that it was acquiring Guidant on December 15, 2004, for $76 a share, with the deal being approved later approved on April 27, 2005, by Guidant shareholders. However, on May 25 of the same year, Guidant reported 26 cases of implantable defibrillator failure, including a death. Johnson & Johnson announced the possibility of them pulling out from the deal, Guidant then sued Johnson & Johnson in an attempt to enforce the acquisition. However they later re-negotiated a lower price of $21.5 billion. |
24 | 2006 | Boston Scientific | Guidant | 25.0 | 38 | A day after Johnson & Johnson raised their price for Guidant to $23.2 billion, Boston Scientific announced a further increased offer. |
25 | 2005 | Boston Scientific | Guidant | 24.6 | 38 | With the lower re-negotiated a lower price of $21.5 billion between Johnson & Johnson and Guidant, Boston Scientific announced an unsolicited offer of $24.6 billion for Guidant (an offer of $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share). |
26 | 2006 | Johnson & Johnson | Guidant | 24.2 | 37 | After Boston Scientific increased their offer to $25 billion, Johnson & Johnson further increased their offer to $24.2 billion. |
27 | 2006 | Johnson & Johnson | Guidant | 23.2 | 35 | After the re-negotiated a lower price of $21.5 billion was trumped by Boston Scientifics offer of $24.6 billion, Johnson & Johnson raised their offer to $23.2 billion. |
28 | 2015 | Endo International | Salix Pharmaceuticals | 11.2 | 14 | Endo withdrew its $11.2 billion cash & stock offer for Salix, ending its plans to outbid Valeant Pharmaceuticals International for the company. [37] |
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).
An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.
Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.
Medicis Pharmaceutical is a medical cosmetics company based in Bridgewater, New Jersey. It is a subsidiary of Valeant Pharmaceuticals, which acquired the company in 2012. Medicis is known for products such as Solodyn and Ziana for treating acne, and for Restylane and Dysport for treating facial wrinkles.
SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after pioneering protein kinases as therapeutic targets and developing the successful cancer therapy sunitinib (Sutent).
David Edmund Ian Pyott CBE was the CEO of Allergan, a pharmaceutical company from 1998 to 2015, when Allergan was acquired by Actavis. In 2014 he was one of the 25 highest-paid CEOs in the United States.
Greenhill & Co., Inc. is an American investment banking advisory firm founded in 1996 by Robert F. Greenhill. The firm provides advice on significant mergers, acquisitions, restructurings, financings, and capital raisings to leading corporations, partnerships, institutions and governments across a number of industries. Since its inception, Greenhill has advised on transactions valued at close to $3 trillion.
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.
Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.